# US Grants Zero-Tariff Window for Selected Medicines From India and 19 Other Nations

> Washington has exempted specific medical categories including rare disease therapies and active ingredients from ad valorem duties, shielding exporters from India and partner countries.

**Type:** article · **Category:** Business · **Published:** 2026-09-29 · **Source:** TrendKia
**Canonical:** https://trendkia.com/en/business/us-davaon-ko-washington-se-bari-rahata-bisa-mulkon-ke-chuninda-medikala-utpadon-para-sima-shulka-shunya-40124 · **Language:** English
**Tags:** Pharma Sector, US Tariffs, Indian Pharma, Donald Trump, US Department of Commerce, Zero Tariff

In a major regulatory development for global healthcare trade, authorities in Washington have decided against levying ad valorem percentage duties on specific categories of medicines and their essential inputs imported from a group of twenty nations, including India. The exemption arrives right on the eve of a broader US move to impose punitive 100% tariffs across several patented pharmaceutical products and specialised drug ingredients.

## Federal Register Details Eligible Partner Jurisdictions
The US Department of Commerce has officially notified the beneficiary nations within the Federal Register, granting a 0% tariff window to certified products arriving from trusted trade partners. Alongside India, the approved roster features twenty entities such as Argentina, Bangladesh, Cambodia, Ecuador, the European Union, Indonesia, Japan, South Korea, Switzerland, the United Kingdom, and Vietnam. Because the United States had planned to activate a stiff 100% customs duty on targeted patented pharmaceuticals and associated items starting 29 September, carving out these critical healthcare categories represents substantial relief for overseas pharmaceutical manufacturers.

## Therapeutic Categories Covered Under the Exemption
Under the criteria established by US regulators, medications engineered for rare disorders, infertility management treatments, advanced cell therapies, gene therapies, and antibody-drug conjugates (ADCs) have all been positioned under the zero-tariff threshold. Importantly, the duty exemption covers not merely the finished therapeutics but also the underlying chemical and biological ingredients required to synthesize them. Furthermore, select veterinary medications have been added to the waiver, assuring manufacturing firms that dispatching these specialized formulations across the Pacific will not trigger costly import surcharges.

## Implications for Generic Exporters and Section 232 Rules
As one of the foremost global suppliers of generic pharmaceuticals, India regards the American marketplace as an essential export destination. Addressing industry concerns, the US Department of Commerce made it clear that baseline generic medicines and their foundational substances remain exempt from the Section 232 pharmaceutical tariffs. This protection is targeted toward manufacturers operating in countries maintaining active or prospective trade and security arrangements with the United States. The policy originates from an earlier proclamation issued on 2 April by President Donald Trump, an order aimed at incentivizing domestic pharmaceutical manufacturing while managing critical supply chains.

## What this means for you
The duty waiver ensures that cross-border shipments of rare disease therapies and advanced medical compounds will avoid steep new tax burdens.

- **For Indian Drug Exporters:** Domestic companies manufacturing specialized therapies and vital ingredients will not absorb punishing import tariffs at US ports. This guarantees steady operating margins and protects long-term supply commitments into the lucrative American healthcare sector.
- **For Patients and Hospitals:** Keeping therapies for rare disorders, cell treatments, and infertility treatments at a 0% rate prevents sudden spikes in clinical acquisition costs. Healthcare providers can continue procuring high-end therapeutics without disruptive price shocks.
- **For Generic Manufacturers:** Clarification that basic generics remain shielded from Section 232 tariffs removes regulatory ambiguity for India's high-volume suppliers. Exporters can proceed with regular shipment schedules without fearing unexpected border surcharges.
- **For International Trade Ties:** Incorporating India within the 20-nation preferential list validates its strategic role in stabilizing critical medical supply lines. This strengthens mutual economic ties between Washington and key Asian manufacturing hubs.

## Why this happened
The exemptions were introduced to balance an aggressive domestic manufacturing drive against the immediate danger of vital medicine shortages across the healthcare system.

- **Primary Catalyst:** The policy stems from an official proclamation issued on 2 April by President Donald Trump designed to boost domestic output of patented medicines by levying heavy tariffs.
- **Supply Chain Realities:** Specialized categories like rare disease formulations, gene therapies, and cell therapies cannot be scaled domestically overnight, necessitating continued overseas supply.
- **Strategic Trade Pacts:** Regulators utilized Section 232 criteria to shield twenty partner nations that maintain current or pending trade and security understandings with Washington.

## Questions & Answers

### 1. Which countries are included in the US zero-tariff pharmaceutical list?
The list includes twenty countries such as India, Bangladesh, Argentina, Cambodia, Ecuador, the European Union, Indonesia, Japan, South Korea, Switzerland, the UK, and Vietnam.

### 2. What categories of medical products qualify for the 0% duty?
Exemptions cover rare disease treatments, infertility medicines, cell therapy, gene therapy, antibody-drug conjugates (ADCs), their essential components, and select veterinary drugs.

### 3. Will standard generic drugs be hit by the 100% US tariffs?
No, the US Department of Commerce clarified that standard generic medicines and their essential ingredients are not subject to Section 232 pharmaceutical tariffs.

### 4. When were the 100% pharmaceutical tariffs scheduled to take effect?
The United States prepared to enact 100% tariffs on targeted patented pharmaceuticals and related components starting 29 September.

### 5. What prompted this tariff policy initially?
The policy aligns with a 2 April proclamation signed by President Donald Trump aimed at accelerating domestic production of patented pharmaceuticals.

---
_TrendKia — Har trend, sabse pehle.. Machine-readable view; canonical HTML at the URL above._